Lupin lands six-month U.S. monopoly on colonoscopy drug Sutab
The company is the exclusive first-to-file generic, securing 180 days of protected sales in a $132.8M branded market.
— 2 earlier stories on Lupin Ltd. →What's new
- Lupin received final U.S. FDA approval for its generic Sutab tablets, a colonoscopy bowel preparation.
- The company is the exclusive first-to-file, earning a 180-day generic exclusivity period.
- The branded drug had estimated annual U.S. sales of $132.8M through March 2026.
Why this matters
First-to-file status is the most valuable prize in the U.S. generic drug market. For 180 days, Lupin will be the sole generic competitor to Sutab, facing no price pressure from other generics. That exclusivity window is where the margin is, not the long-term volume.
What we're watching
- The pace of market share capture during the 180-day exclusivity window.
- The eventual launch of competing generics after the exclusivity period ends.
- Financial impact in coming quarterly results from this U.S. launch.
The full read
Lupin won a 180-day U.S. monopoly on the colonoscopy drug Sutab. The U.S. FDA granted final approval for its generic version, and because Lupin was the exclusive first-to-file, no other generic can enter the market until that exclusivity window closes. The branded drug generated $132.8 million in annual U.S. sales through March 2026. The real play is the exclusivity margin. For six months, Lupin is the only generic game in town, meaning it can price closer to the branded drug and capture outsized profits on what is, by revenue, a modest market. Manufacturing will happen at its Nagpur plant. This is a classic high-margin, limited-duration payoff from the U.S. ANDA filing strategy.
Questions answered
- What does 'exclusive first-to-file' mean for Lupin?
- It means Lupin was the only company to file an ANDA with a paragraph IV certification before the branded company's patent challenges were resolved. This grants it a 180-day period where the FDA cannot approve any other generic version of Sutab.
- How significant is the $132.8M in sales for Lupin's overall business?
- The reference branded sales are $132.8M annually. The rationale estimates the revenue contribution will be around 1% of Lupin's total group revenue, but the profitability during the six-month monopoly will be disproportionately high.
- Which Lupin facility will manufacture the drug?
- The generic Sutab tablets will be manufactured at Lupin's facility in Nagpur, India.
- What is the next milestone after the 180-day exclusivity?
- After the 180 days, other generic manufacturers can receive FDA approval and enter the market, which will quickly erode price and market share for Lupin's version.
Story so far
All notes on LUPIN →- 29 May 2026 · 8:37 PM IST Lupin lands six-month U.S. monopoly on colonoscopy drug Sutab
- 1d ago Lupin wins US FDA nod for generic Halaven, but the prize is tiny
- 12d ago Lupin wins its first drug approval in China